Abbott v. Medtronic
This article was originally published in The Gray Sheet
Advanced Cardiovascular Solutions, a subsidiary of Abbott Laboratories formerly owned by Guidant, did not commit "inequitable conduct" to obtain stent technology that is also incorporated into Medtronic's S7 and Driver coronary stents, a U.S. District Court in Delaware rules April 24. The ruling completes the liability phase of a patent case originally brought by Guidant against Medtronic Vascular, although Medtronic says it will appeal (1"The Gray Sheet" March 21, 2005, p. 24). Medtronic also says that the decision does not impact the ongoing United States Patent and Trademark Office proceedings on the same patent. The USPTO is reexamining whether Guidant's so-called "Lau patents" are valid in light of Medtronic's claims of "prior art"...
You may also be interested in...
Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets
Medtronic's Endeavor drug-eluting stent program and current coronary stent line-up are unaffected by a recent Johnson & Johnson patent infringement ruling against the company, Medtronic insists
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients